Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.62 |
| ▸ | MMP2 | P08253 | 9/20 | 0.62 |
| ▸ | MMP8 | P22894 | 5/20 | 0.60 |
| ▸ | MMP13 | P45452 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640662 | 1.00 | MMP9 (0.62) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13640694 | 0.94 | MMP9 (0.56) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL16330736 | 0.91 | MMP9 (0.65) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13639206 | 0.91 | MMP9 (0.70) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13639260 | 0.91 | MMP9 (0.70) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13570809 | 0.91 | MMP9 (0.70) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13639204 | 0.90 | MMP9 (0.60) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13639202 | 0.90 | MMP9 (0.60) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13570906 | 0.90 | MMP9 (0.60) | MMP9MMP2MMP8MMP13PTPN1 | |
| SCHEMBL13640663 | 0.90 | MMP9 (0.52) | MMP9MMP2MMP8MMP13PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP9 4/4885MMP2 16/4885MMP8 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.